"This decade will be defined by the affordability crisis and our vision as a company is to solve the affordability crisis in US healthcare," apree health CEO Donald Trigg explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Trigg joins BI senior health care analyst Jonathan Palmer for a deep dive into apree's advanced primary care and digital engagement capabilities, how the combination of Vera Whole Health and Castlight positions the company to bring a differentiated solution set to help employers as well as health plans improve outcomes while lowering costs, and its progress in proving out its thesis across distinct market models. 

"This decade will be defined by the affordability crisis and our vision as a company is to solve the affordability crisis in US healthcare," apree health CEO Donald Trigg explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Trigg joins BI senior health care analyst Jonathan Palmer for a deep dive into apree's advanced primary care and digital engagement capabilities, how the combination of Vera Whole Health and Castlight positions the company to bring a differentiated solution set to help employers as well as health plans improve outcomes while lowering costs, and its progress in proving out its thesis across distinct market models.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care by Bloomberg Intelligence

Apree Health's New Approach to Integrated Care Networks

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/c475fea4-f2c0-411c-baed-b0c9014e04fc/transcript

“I think this is going to be the most eventful ASCO for biotech in a while,” says Dr. Roderick Wong, founder of RTW Investments, referring to the annual meeting of the American Society of Clinical Oncology. Wong joins Bloomberg Intelligence analyst Sam Fazeli on the Vanguards of Health Care podcast to break down biotech’s rebound, why fundamentals may finally be improving after a prolonged bear market and how China’s speed and cost advantages are reshaping global drug discovery. They also explore AI’s potential to improve clinical success rates, rare-disease regulatory flexibility and why oncology, neuropsych and immunology remain fertile ground for innovation.

&ldquo;I think this is going to be the most eventful ASCO for biotech in a while,&rdquo; says Dr. Roderick Wong, founder of RTW Investments, referring to the annual meeting of the American Society of Clinical Oncology. Wong joins Bloomberg Intelligence analyst Sam Fazeli on the Vanguards of Health Care podcast to break down biotech&rsquo;s rebound, why fundamentals may finally be improving after a prolonged bear market and how China&rsquo;s speed and cost advantages are reshaping global drug discovery. They also explore AI&rsquo;s potential to improve clinical success rates, rare-disease regulatory flexibility and why oncology, neuropsych and immunology remain fertile ground for innovation.

RTW’s Rod Wong on Biotech’s Revival and the Global Shift

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/45032524-8327-4f41-b472-b442011ec8d4/transcript

“It’s crazy to think that that would be the expectation in cancer care, yet we expect that of families in autism,” says Neil Hattangadi, CEO and co-founder of Cortica. Hattangadi joins Bloomberg Intelligence analyst Jonathan Palmer to explain why autism care remains so fragmented and how Cortica is trying to replace siloed services with a coordinated whole-child model. They discuss why applied behavior analysis (ABA) should be one tool, not the whole answer, how Cortica integrates medical and behavioral care, and why better coordination could ease the burden on families while improving outcomes.

&ldquo;It&rsquo;s crazy to think that that would be the expectation in cancer care, yet we expect that of families in autism,&rdquo; says Neil Hattangadi, CEO and co-founder of Cortica. Hattangadi joins Bloomberg Intelligence analyst Jonathan Palmer to explain why autism care remains so fragmented and how Cortica is trying to replace siloed services with a coordinated whole-child model. They discuss why applied behavior analysis (ABA) should be one tool, not the whole answer, how Cortica integrates medical and behavioral care, and why better coordination could ease the burden on families while improving outcomes.

Cortica’s Plan to Bring Value-Based Care to Autism

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d2a175c4-7e93-4e20-bb23-b43b01309d51/transcript

“More than half of your time as a public company CEO is devoted to things that are not drug development,” Xontogeny CEO Chris Garabedian says. Garabedian joins Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast to explain why he earlier left the track of operating public companies to back biotech, where better decisions can create the biggest value inflections. He discusses what separates real drug developers from scientists, why early biotech mistakes are often irreversible, how Xontogeny evaluates new companies, and why AI may improve research tools faster than it transforms human biology.

&ldquo;More than half of your time as a public company CEO is devoted to things that are not drug development,&rdquo; Xontogeny CEO Chris Garabedian says. Garabedian joins Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast to explain why he earlier left the track of operating public companies to back biotech, where better decisions can create the biggest value inflections. He discusses what separates real drug developers from scientists, why early biotech mistakes are often irreversible, how Xontogeny evaluates new companies, and why AI may improve research tools faster than it transforms human biology.

Xontogeny's Case for Drug Developers Over Storytellers

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/31191c13-2f42-4d53-97d3-b43400fd2b53/transcript

Apree Health's New Approach to Integrated Care Networks

In 1 playlist(s)

Vanguards of Health Care by Bloomberg Intelligence

Social links

Follow podcast

Recent clips